Aligos Therapeutics, Inc. Common Stock

ALGSNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
5.57 USD
↗ 0.07 (1.27%)AT CLOSE (11:59 AM EDT)
5.58
↗ 0.01 (0.09%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
5.58
↗ 0.01 (0.09%)
🔴Market: CLOSED

ALGS is currently priced at $5.57. ALGS shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place ALGS at a fair price relative to peers.

Technical & fundamental data as of Jun 26, 2026.

Open?$5.34
High?$5.74
Low?$5.30
Prev. Close?$5.50
Volume?54.4K
Avg. Volume?105.5K
VWAP?$5.51
Rel. Volume?0.52x
Bid / Ask
Bid?$4.70 × 100
Ask?$6.83 × 100
Spread?$2.13
Midpoint?$5.77
Valuation & Ratios
Market Cap?34.5M
Shares Out?5.4M
Float?4.8M
Float %?89.2%
P/E Ratio?N/A
P/B Ratio?1.08
EPS?-$14.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesBiotech - Drug Development›Metabolic & Cardiometabolic
Employees
82
Market Cap
34.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.aligos.com
Listed
2020-10-16
Address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (800) 466-6059
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
35
Short Sent.?
49
Piotroski F-Score?2/9Weak
Altman Z-Score?-17.94Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.72%High
Short Interest?611.7K
Days to Cover?6.1
Free Float4.8M
Avg Daily Volume99.8K
Settlement Date2026-06-15
Financial Health
Current Ratio?2.55Strong
Quick Ratio?2.55Strong
Cash Ratio?1.29Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
1.08CHEAP▾
P/S?
Peers
100
S&P
16
7.33HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.1CHEAP▾
EV/Sales?
Peers
100
S&P
92
0.97CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-284.1%WEAK▾
ROA?
S&P
3
-139.9%WEAK▾
Cash Flow & Enterprise
FCF?$-85185000
Enterprise Value?$4.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist